SCHEMBL16245582

SCHEMBL16245582

CCOC(=O)CCCOc1ccc(Nc2nc(Nc3ccc(CCCNC(=O)OC(C)(C)C)cc3)ncc2[N+](=O)[O-])cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.47
▸ GSK3A P49840 3/20 0.47
▸ AURKA O14965 2/20 0.47
▸ ITK Q08881 3/20 0.47
▸ PTK2 Q05397 3/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ MCL1 Q07820 1/20 0.44
▸ PTK2B Q14289 1/20 0.44
▸ EGFR P00533 5/20 0.43
▸ FGFR1 P11362 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CA12 O43570 3/20 0.39
▸ CA1 P00915 3/20 0.39
▸ CA2 P00918 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245562 0.98 GSK3B (0.47) GSK3BGSK3AAURKAITKPTK2
SCHEMBL16245581 0.95 ITK (0.52) GSK3BGSK3AAURKAITKPTK2
SCHEMBL16245595 0.93 ITK (0.51) GSK3BGSK3AAURKAITKPTK2
SCHEMBL16245548 0.88 ITK (0.49) AURKAITKMAPTEGFRFGFR1
SCHEMBL16245576 0.88 EGFR (0.46) GSK3BGSK3AAURKAITKPTK2
SCHEMBL18869355 0.87 GSK3B (0.46) GSK3BGSK3AAURKAPTK2MEN1
SCHEMBL16245565 0.86 ITK (0.49) AURKAITKMAPTEGFRFGFR1
SCHEMBL16245569 0.82 ITK (0.54) AURKAITKMAPTEGFRCA12
SCHEMBL16246173 0.80 ITK (0.54) AURKAITKMAPTEGFRCA12
SCHEMBL16245542 0.80 RPS6KA3 (0.52) ITKMEN1KMT2AEGFRFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
EP-2994471-A1 MACROCYCLES AS KINASE INHIBITORS Merck Patent GmbH (DE) 2016-03-16 — — EP disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS EIF2AK4, CDK2, CDK1 GSK3B 482/4885GSK3A 523/4885AURKA 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback